Forty Seven, Inc. Reports Third Quarter 2019 Financial Results and Recent Business Highlights
November 12, 2019 07:01 ET
|
Forty Seven, Inc.
-- On-Track to Initiate Potential Registration-Enabling Trials in MDS and DLBCL in 1Q 2020 ---- Entered into Collaboration with bluebird bio to Evaluate Antibody-Based Conditioning Regimen in...
Forty Seven, Inc. to Present New Clinical and Preclinical Data on Magrolimab and FSI-174 at 61st ASH Annual Meeting
November 06, 2019 09:01 ET
|
Forty Seven, Inc.
MENLO PARK, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (NASDAQ:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight...
Forty Seven Inc. to Report Third Quarter 2019 Financial Results on Tuesday, November 12, 2019
November 05, 2019 08:01 ET
|
Forty Seven, Inc.
MENLO PARK, Calif., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Forty Seven Inc. (NASDAQ:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight...
Forty Seven Inc. to Present at 2019 Cantor Global Healthcare Conference
September 27, 2019 08:01 ET
|
Forty Seven, Inc.
MENLO PARK, Calif., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Forty Seven Inc. (NASDAQ:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight...
Forty Seven Inc. to Present at Morgan Stanley 17th Annual Global Healthcare Conference
September 03, 2019 16:01 ET
|
Forty Seven, Inc.
MENLO PARK, Calif., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Forty Seven Inc. (NASDAQ:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight...
Forty Seven, Inc. Granted Fast Track Designation for Magrolimab (5F9) for the Treatment of Myelodysplastic Syndrome and Acute Myeloid Leukemia
September 03, 2019 08:01 ET
|
Forty Seven, Inc.
MENLO PARK, Calif., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Forty Seven, Inc., a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against...
Forty Seven Inc. Reports Second Quarter 2019 Financial Results and Recent Business Highlights
August 13, 2019 16:01 ET
|
Forty Seven, Inc.
-- Presented Updated Data for 5F9 in Four Patient Populations at ASCO and EHA Meetings ---- Received FDA Feedback Suggesting Single-Arm Pivotal Trials May Support Registration in MDS and DLBCL ----...
Forty Seven Inc. to Report Second Quarter 2019 Financial Results on Tuesday, August 13, 2019
August 06, 2019 16:01 ET
|
Forty Seven, Inc.
MENLO PARK, Calif., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Forty Seven Inc. (NASDAQ:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight...
Forty Seven, Inc. Announces $6 Million in Funding from the Leukemia & Lymphoma Society TAP to Accelerate the Development of 5F9 in Myelodysplastic Syndrome
August 06, 2019 08:01 ET
|
Forty Seven, Inc.
MENLO PARK, Calif., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Forty Seven, Inc., a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against...
Forty Seven Inc. to Present at Canaccord Genuity 39th Annual Growth Conference
July 31, 2019 08:01 ET
|
Forty Seven, Inc.
MENLO PARK, Calif., July 31, 2019 (GLOBE NEWSWIRE) -- Forty Seven Inc. (NASDAQ:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight...